Forum: Pieris Pharmaceuticals » Forum Pieris Pharmaceuticals geopend | DeBeurs.nl

Pieris Pharmaceuticals « Terug naar discussie overzicht

Forum Pieris Pharmaceuticals geopend

13 Posts
Aantal posts per pagina:  20 50 100 | Omlaag ↓
IEX - Forummoderator
1
Pieris Pharmaceuticals is a clinical stage biotechnology company that discovers and develops Anticalin-based drugs to target validated disease pathways in a unique and transformative way. Our pipeline includes immuno-oncology multi-specifics tailored for the tumor micro-environment, an inhaled Anticalin to treat uncontrolled asthma and a half-life-optimized Anticalin to treat anemia. Proprietary to Pieris, Anticalin proteins are a novel class of therapeutics validated in the clinic and by partnerships with leading pharmaceutical companies.

Anticalin proteins are engineered versions of lipocalins, human proteins that naturally bind, store and transport a wide spectrum of molecules. Our libraries of more than 100 billion different Anticalin proteins have repeatedly delivered drug candidates binding to a very broad spectrum of therapeutic targets.

Pieris has established a diverse pipeline of Anticalin therapeutics for a number of different indications and has R&D collaborations with Servier, Roche, Daiichi Sankyo, the Sanofi Group and others.

Pieris is listed on the NASDAQ and trades under the ticker symbol PIRS.

Groet Henk
Beurspleintje
1
Bedankt voor het openen van het forum voor dit prachtige potentiële aandeel.
Dan kunnen we elkaar op de hoogte houden van ontwikkelingen en nieuws.

Beurspleintje.
[verwijderd]
1
Bedankt voor het openen, ziet er inderdaad beloftevol uit voor de lange termijn.
American based early stage biotech met brede pijplijn gebaseerd op Anticalins.
Voorlopig nog genoeg cash en recentelijk nog grote deals gesloten met Servier en ASKA pharmaceuticals.
CEO vroeger bij Morphosys gezeten en lijkt me dat ze op dezelfde manier proberen te groeien, dus door middel van financiering door partnerships.

Redelijk wat institutionele partijen al ingestapt en analyst coverage met koersdoelen tussen de 6$ en 8$.
Zie dit in de komende jaren wel richting de 20$ lopen en heb dan ook alvast een kleine positie ingenomen.

Nog wat info tav Pieris:

seekingalpha.com/article/4045575-biot...
pieris-pharmaceuticals

www.pieris.com/about/management-team

www.fiercebiotech.com/biotech/servier...

seekingalpha.com/article/3531706-dept...

seekingalpha.com/article/3329015-nasd...

PapaPieris
0
Beurspleintje
1
Pieris Pharmaceuticals to Host Conference Call on Strategic Alliance With AstraZeneca

Download PDF

BOSTON, MA -- (Marketwired) -- 05/03/17 -- Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), today announced a strategic collaboration in respiratory disease with AstraZeneca to develop novel inhaled biologics that leverage Pieris' Anticalin® platform, led by its drug candidate targeting IL-4 receptor alpha, PRS-060.

Pieris will host an investor conference call on Wednesday, May 3, 2017 at 10:00 AM (EDT) / 03:00 PM (BST) to discuss the collaboration. To access the call, participants may dial 1-877-407-8920 (US & Canada) or 1-412-902-1010 (International) at least 10 minutes prior to the start of the call.

An archived replay of the call will be available by dialing 1-877-660-6853 (US & Canada) or 1-201-612-7415 (International) and providing the Conference ID #13661472.

About Pieris Pharmaceuticals :

Pieris is a clinical-stage biotechnology company that discovers and develops Anticalin-based drugs to target validated disease pathways in a unique and transformative way. Our pipeline includes immuno-oncology multi-specifics tailored for the tumor micro-environment, an inhaled Anticalin to treat uncontrolled asthma and a half-life-optimized Anticalin to treat anemia. Proprietary to Pieris, Anticalin proteins are a novel class of therapeutics validated in the clinic and by partnerships with leading pharmaceutical companies. Anticalin®, is a registered trademark of Pieris. Pieris has partnerships with Servier, ASKA, Roche, Sanofi, Daiichi Sankyo and Zydus. For more information visit www.pieris.com.

Forward Looking Statements

This press release contains forward-looking statements as that term is defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Statements in this press release that are not purely historical are forward-looking statements. Such forward-looking statements include, among other things, references to novel technologies and methods; our business and product development plans and timelines; the timing and progress of our studies, development of therapeutic programs; ability to receive research funding; our liquidity and ability to fund our future operations; our ability to achieve certain milestones and receive future milestone or royalty payments; current or future partnerships; or market information. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, our ability to raise the additional funding we will need to continue to pursue our business and product development plans; the inherent uncertainties associated with developing new products or technologies and operating as a development stage company; our ability to develop, complete clinical trials for, obtain approvals for and commercialize any of our product candidates; competition in the industry in which we operate and market conditions. These forward-looking statements are made as of the date of this press release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law. Investors should consult all of the information set forth herein and should also refer to the risk factor disclosure set forth in the reports and other documents we file with the SEC available at www.sec.gov, including without limitation the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2016 and the Company's Quarterly Reports on Form 10-Q.
FatCool
0
Net een paar dagen te laat gekocht. Had gisteren order ingelegd op $2.37 voor 6000 aandelen. Kreeg er uiteindelijk slechts 200 toebedeeld :).

Vanmiddag in de herkansing. Een mooie pluk gekocht op $3.33.

fc
FatCool
0
Pieris Pharmaceuticals and AstraZeneca Collaborate to Develop and Commercialize Anticalin-Based Inhaled Treatments for Respiratory Diseases

BOSTON, MA - (Marketwired - May 03, 2017) - Pieris Pharmaceuticals, Inc. (PIRS)

* Pieris to receive $57.5 million USD in upfront and near-term milestone payments
* Pieris has the potential to receive development-dependent milestones and eventual commercial payments for all products not exceeding $2.1 billion as well as tiered royalties
* For programs co-developed by Pieris, the Company will be entitled to receive increased royalties or a gross margin share on worldwide sales, dependent on the level of investment to which Pieris commits
* Pieris will host a conference call on Wednesday, May 3rd at 10am EDT to discuss the collaboration

Pieris today announced a strategic collaboration in respiratory diseases with AstraZeneca to develop novel inhaled drugs that leverage Pieris' Anticalin® platform, including its lead preclinical drug candidate, PRS-060.

Anticalin molecules are engineered proteins which can mimic antibodies by binding to sites either on other proteins or on small molecules. They are smaller than monoclonal antibodies, offering the potential of direct delivery to the lung.

Under the collaboration, Pieris will be responsible for advancing its preclinical lead candidate, PRS-060, into Phase 1 clinical trials in 2017. PRS-060 is an Anticalin against interleukin-4 receptor alpha (IL-4Ra) with potential in asthma. AstraZeneca will fund all clinical development and subsequent commercialization programs and Pieris has the option of co-development and co-commercialization in the US from Phase 2a onwards. In addition, the parties will collaborate to progress four additional novel Anticalins against undisclosed targets for respiratory diseases with Pieris having the option to co-develop and co-commercialize in the US two of these programs.

Mene Pangalos, Executive Vice President, Innovative Medicines and Early Development Biotech Unit and Business Development, said: "At AstraZeneca, discovering and developing innovative new medicines to treat respiratory diseases is a key strategic priority. Our alliance with Pieris adds an important new modality to our respiratory portfolio and builds on our scientific expertise in inhaled formulation technologies. Pieris shares our passion for ground-breaking science and we look forward to working together to develop new, life-changing treatment options for patients."

Stephen Yoder, President and Chief Executive Officer of Pieris, said: "Our partnership with AstraZeneca accelerates the transformation of Pieris into a fully-integrated drug development and commercial organization, comprising two main pillars in immunology: respiratory diseases and immuno-oncology, each of which is now anchored by a major alliance. We recognize AstraZeneca's unparalleled expertise in the development of inhaled drugs, which will maximize the potential of PRS-060 and other inhaled Anticalin molecules to become valuable assets for both companies."

AstraZeneca will make an upfront and near term milestone payments to Pieris in the amount of $57.5 million -- $45 million USD of upfront payments and $12.5 million USD for the initiation of the PRS-060 Phase 1 trial. Pieris has the potential to receive development-dependent milestones and eventual commercial payments for all products not exceeding $2.1 billion as well as tiered royalties on the sales of any potential products commercialized by AstraZeneca. For programs co-developed by Pieris, the Company stands to receive increased royalties or a gross margin share on worldwide sales equal, dependent on the level of investment to which Pieris commits.

Louis Matis, M.D., Senior Vice President and Chief Development Officer of Pieris, said: "AstraZeneca, a leading innovator in respiratory diseases with considerable expertise in the development of inhaled products, is the ideal partner to exploit the potential of our platform in respiratory diseases. Based on the limitations of many types of biologic molecules, direct delivery to the lungs via inhalation has been challenging to date for other classes of therapeutic proteins. Anticalin proteins have unique properties, not least of which is their size and stability, and show considerable promise for this route of delivery."

The collaboration agreement is conditional upon the expiration or early termination of the applicable waiting period (and any extension thereof) under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended.

PRS-060, an Anticalin protein potently engaging IL-4Ra, is being developed for patients suffering from moderate to severe asthma, many of whom are not able to control their asthma well with currently available medications. In a large proportion of asthma patients, the Th2 pathway plays an important role. IL-4 and IL-13 are the main cytokines involved in Th2-mediated asthma. Both signal via IL-4Ra, making IL-4Ra a cornerstone intervention point. PRS-060 differentiates from antibody approaches through inhaled delivery directly into the lungs, potentially resulting in efficacy and safety benefits. The local delivery may allow for lower doses than systemically administered antibodies, potentially also resulting in a significant cost of goods advantage over those therapies. Pieris has demonstrated proof of concept in animals as well as feasibility for pulmonary delivery with PRS-060.
FatCool
0
Boston-based Pieris adds AstraZeneca as R&D partner in $45M deal

May 3, 2017, 9:49am EDT

Shares of Pieris Pharmaceuticals soared on Wednesday after the tiny Boston biotech announced yet another collaboration with a big pharma company, this time grabbing $45 million upfront from AstraZeneca to develop inhalable respiratory disease drugs.

Under the agreement, Pieris (Nasdaq: PIRS) will get $45 million plus an additional $12.5 million once it begins a Phase 1 trial of its lead drug, a potential asthma treatment called PRS-060. Like others in its pipeline, the drug is an "anticalin" — an engineered protein that is supposed to be safer, easier to deliver and more effective than targeted biologic drugs.

U.K.-based AstraZeneca (NYSE: AZN) will fund development and commercialization of PRS-060, while Pieris will have the option to co-develop and co-commercialize the drug in the U.S. from mid-stage studies onward. In addition, the companies will collaborate to advance four more anticalins targeting respiratory diseases, with Pieris getting an option to co-develop and co-commercialize two of them.

Potential milestone payments from the deal could reach $2.1 billion, the companies said.

Shares of Pieris jumped 30 percent on the news when markets opened Wednesday.

The company was founded in Germany in 2001 and went public in the U.S. in 2014 through a reverse merger. Pieris now has about 40 employees in Munich, where its labs are located, plus another nine employees at its corporate headquarters at 255 State Street in Boston.

With the AstraZeneca deal, Pieris adds to a formidable roster of partners. The company previously inked collaborations with Roche, Allergan, Sanofi (NYSE: SNY) and Daiichi Sankyo. More recently, Pieris announced an agreement with French giant Servier in January to co-develop up to eight cancer programs. That deal included a $31 million upfront payment plus up to $1.7 billion in potential milestones.

www.bizjournals.com/boston/news/2017/...
FatCool
0
Mooi overzichts artikel.

seekingalpha.com/article/4070775-pier...

Positie in PIRS flink uitgebreidt de laatste dagen.

Donderdag 11 mei de kwartaalcijfers.

fc
Topperke
0
Te laat om in te stappen?
ZOu er nog een dipje komen om te kopen?
Lijkt me echt een topaandeel, waar nog te weinig beleggers besef van hebben.
Over enkele jaren kunnen ze enorme milestone payments ontvangen.
Ik denk dat dit op lange termijn minstens een miljard moet waard zijn. Das 4x zoveel als nu.
Beurspleintje
0
Het is zeker niet te laat om in te stappen, ik zie het vooral als een lange termijn parel.
13 Posts
Aantal posts per pagina:  20 50 100 | Omhoog ↑

Plaats een reactie

Meedoen aan de discussie?

Word nu gratis lid of log in met uw e-mailadres en wachtwoord.

Direct naar Forum

Detail

Vertraagd 14 feb 2020 22:00
Koers 3,730
Verschil -0,230 (-5,81%)
Hoog 3,989
Laag 3,720
Volume 287.619
Volume gemiddeld 530.900
Volume gisteren 101.314